Treatment News : Poor Adherence Crippled PrEP Efficacy in Women’s Study - by Tim Horn

POZ - Health, Life and HIV
Subscribe to:
POZ magazine
Newsletters
Join POZ: Facebook MySpace Twitter Pinterest
Tumblr Google+ Flickr MySpace
POZ Personals
Sign In / Join
Username:
Password:

Back to home » Treatment News » March 2012

Most Popular Links
Most Popular Lessons

The HIV Life Cycle

Shingles

Herpes Simplex Virus

Syphilis & Neurosyphilis

Treatments for Opportunistic Infections (OIs)

What is AIDS & HIV?

Hepatitis & HIV

15 Years Ago In POZ


More Treatment News

Click here for more news

Have news about HIV? Send press releases, news tips and other announcements to news@poz.com.


emailprint

March 7, 2012

Poor Adherence Crippled PrEP Efficacy in Women’s Study

by Tim Horn

CROI 2012 In stark contrast with the encouraging results from Partners PrEP—a clinical trial of Viread (tenofovir) and Truvada (tenofovir plus emtricitabine) pre-exposure prophylaxis in mixed-status heterosexual couples—a study focusing specifically on women at risk for HIV infection found no difference in infection rates between those using daily PrEP and those using placebo, according to results presented at the 19th Conference on Retroviruses and Opportunistic Infections in Seattle.

Despite substantial counseling efforts in the study, Lut Van Damme, MD, PhD, of the Setshaba Research Center in Pretoria, South Africa, and her FEM-PrEP trial colleagues reported that inadequate adherence likely undermined the trial’s ability to fully assess the effectiveness of Truvada as PrEP in this particular population.

FEM-PrEP originally planned to enroll 4,000 women, before it was discontinued by its sponsor, Family Health International (FHI), in April 2011 because of efficacy concerns. According to Van Damme, 2,120 women residing in Kenya, Tanzania and South Africa were randomized to receive either daily Truvada or placebo before the trial was terminated.

Van Damme noted that the women enrolled in FEM-PrEP were considered to be at high risk for HIV infection. Roughly 60 percent of the women were younger than 25; about 12 percent reported having sex for gifts or money with non-primary partners; only half reported condom use; and 70 percent thought they had little or no perceived chance of contracting HIV.

Thirty-three of the 1,024 women in the Truvada group became infected with HIV during the study. Of the 1,032 women in the placebo group, 35 became infected. In other words, 4.7 percent of the Truvada-treated women and 5 percent of the women who received placebo were ultimately infected with the virus.

Van Damme and her colleagues estimated the overall effectiveness of Truvada in FEM-PrEP to be 6 percent, but this reduced risk was not statistically significant—it could have easily occurred by chance.

As for differences in safety, the researchers noted that nausea and vomiting were more frequent in the Truvada group. Mild-to-moderate increases in two liver enzymes (ALT and AST) were also more common in the Truvada group, though only the difference in ALT measurements was statistically significant. No differences in creatinine or phosphorous levels were seen between the two study groups.

Drug-resistance data were available for 35 women in the Truvada group and 40 women in the placebo group. Though no women in the study had HIV with the K65R mutation, which confers resistance to the tenofovir in Truvada (and Viread), three women in the active PrEP group and one woman in the placebo group developed resistance to the emtricitabine (and lamivudine).

Douglas Dieterich  

Lut Van Damme, MD, PhD, reviews results from FEM-PrEP at the 19th Conference on Retroviruses and Opportunistic Infections in Seattle.
©Tim Horn Photos

 
Adherence Shortcomings

Similar to the other major PrEP studies—Partners PrEP as well as the iPrEx study in men who have sex with men and transgender women—rudimentary adherence measurements conducted by the FEM-PrEP researchers failed to hint at anything being remiss. According to Van Damme, 95 percent of the women said they took their pills as recommended in the study and an even greater number said they found the Truvada tablets or matching placebos to be easy to take. Pill counts suggested the adherence rate was 86 percent in the Truvada group and 89 percent in the placebo group.

Measurements of drug levels in study volunteers’ blood told a very different story. Though Van Damme and her colleagues were unable to measure drug levels precisely at the time the women were infected, they were able to look at samples collected during the visit before a subset of women were infected and during the visit at the time HIV was diagnosed.

In the women who became infected, roughly a quarter had blood levels of tenofovir at either visit, a finding that suggests most participants weren’t using the drug properly.

Results weren’t much better among women randomized to the Truvada group who didn’t become infected in the study. Roughly a third of these women had adequate levels of tenofovir in their blood during subsequent clinic visits.

FEM-PrEP vs. Partners PrEP

Biomedical prevention experts, including members of the Partners PrEP and FEM-PrEP study teams, are still attempting to make heads or tails of the different outcomes seen in both trials.

During a CROI press conference, held Monday, March 5, at the Washington State Convention Center, Partners PrEP investigator Jared Baeten, MD, noted one key difference: The women in Partners PrEP were in stable relationships and, thus, may have been encouraged by their HIV-positive male partners to adhere to treatment.

Baeten reiterated other major differences, including the facts that women in FEM-PrEP were younger than those enrolled in Partners PrEP and were more likely to have other sexually transmitted infections and that they largely considered themselves not to be at risk for HIV.

But it is adherence, Baeten said, that is the driver of PrEP efficacy and will ultimately need to be a major focus of follow-up studies and demonstration projects going forward.

Search: FEM-PrEP, women, pre-exposure prophylaxis, Truvada, tenofovir, emtricitabine, adherence, Africa, Van Damme, CROI, Seattle


Scroll down to comment on this story.



Name:

(will display; 2-50 characters)

Email:

(will NOT display)

City:

(will display; optional)

Comment (500 characters left):

(Note: The POZ team reviews all comments before they are posted. Please do not include either ":" or "@" in your comment. The opinions expressed by people providing comments are theirs alone. They do not necessarily reflect the opinions of Smart + Strong, which is not responsible for the accuracy of any of the information supplied by people providing comments.)

Comments require captcha.
Please enter this number for verification:

| Posting Rules



Show comments (0 total)

 
[Go to top]


Facebook Twitter Google+ MySpace YouTube Tumblr Flickr Instagram
Quick Links
Current Issue

HIV Testing
Safer Sex
Find a Date
Newly Diagnosed
HIV 101
Disclosing Your Status
Starting Treatment
Help Paying for Meds
Search for the Cure
POZ Stories
POZ Opinion
POZ Exclusives
Read the Blogs
Visit the Forums
Job Listings
Events Calendar


    dversescott
    Baltimore
    Maryland


    slimcuteguy
    Asheville
    North Carolina


    TaintedloveDC
    Washington
    DC


    donnyp
    liberty
    Kentucky
Click here to join POZ Personals!
Ask POZ Pharmacist

Talk to Us
Poll
Are you a regular coffee drinker?
Yes
No

Survey
Pop Watch

more surveys
Contact Us
We welcome your comments!
[ about Smart + Strong | about POZ | POZ advisory board | partner links | advertising policy | advertise/contact us | site map]
© 2014 Smart + Strong. All Rights Reserved. Terms of use and Your privacy.
Smart + Strong® is a registered trademark of CDM Publishing, LLC.